Anteris Technologies Global Corp.
- Open
- 8.48
- Day high
- 8.63
- Day low
- 8.48
- Prev close
- 8.61
- Volume
- 26K
- Mkt cap
- $832M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 3.3
- P/S
- 371.2
- Yield
- —
- Per share
- —
- ▲Insiders net buying $3.6M over the last 3 months (3 open-market buys, 14 sales)
- 🏛Institutions mixed (13F)
Anteris Technologies Global Corp. (AVR) is a Healthcare company listed on NASDAQ. The stock is up 108% over the past year. Over the trailing 3 months, insiders filed 3 open-market buys and 14 sales (SEC Form 4).
Anteris Technologies Global Corp. (AVR) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
AVR earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 11, 2026 | $-0.21 | $-0.30 | -44.7% | $1M | -32.7% |
| May 12, 2026 | $-0.27 | $-0.28 | -3.4% | $494000 | -35.6% |
| Nov 12, 2025 | $-0.56 | $-0.62 | -10.7% | $429000 | +39.5% |
| Apr 29, 2025 | — | $-0.82 | — | $536112 | — |
AVR insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 1, 2026 | L1 Capital Pty Ltd10 percent owner | Sell | 7,800 | $8.83 |
| Aug 20, 2026 | St Denis Daviddirector, officer: Chief Operating Officer | Tax | 45,072 | $9.58 |
| Aug 20, 2026 | St Denis Daviddirector, officer: Chief Operating Officer | Option | 60,000 | $5.65 |
| Aug 12, 2026 | L1 Capital Pty Ltd10 percent owner | Sell | 251,844 | $9.10 |
| Aug 12, 2026 | L1 Capital Pty Ltd10 percent owner | Sell | 375,815 | $9.30 |
| Aug 10, 2026 | L1 Capital Pty Ltd10 percent owner | Sell | 174,721 | $8.10 |
| Aug 6, 2026 | L1 Capital Pty Ltd10 percent owner | Sell | 480,608 | $8.30 |
| Aug 6, 2026 | L1 Capital Pty Ltd10 percent owner | Sell | 14,581 | $8.23 |
| Aug 4, 2026 | L1 Capital Pty Ltd10 percent owner | Sell | 48,711 | $8.15 |
| Aug 4, 2026 | L1 Capital Pty Ltd10 percent owner | Sell | 475,693 | $8.10 |
| Jul 31, 2026 | L1 Capital Pty Ltd10 percent owner | Sell | 155,505 | $8.04 |
| Jul 31, 2026 | L1 Capital Pty Ltd10 percent owner | Sell | 558,633 | $8.20 |
| Jul 29, 2026 | L1 Capital Pty Ltd10 percent owner | Sell | 232,817 | $8.19 |
| Jul 29, 2026 | L1 Capital Pty Ltd10 percent owner | Sell | 208,731 | $8.09 |
| Jul 28, 2026 | L1 Capital Pty Ltd10 percent owner | Buy | 1,333,334 | — |
Source: AVR SEC Form 4 filings, latest Sep 1, 2026. For informational purposes only — not investment advice.
See the full AVR insider & 13F page →Anteris Technologies Global Corp. company profile
Overview
Anteris Technologies Global Corp. (NASDAQ:AVR) is an Australian-based structural heart company that develops medical devices for treating aortic stenosis, a condition where the heart's aortic valve becomes narrowed and restricts blood flow. Founded in 1999 and headquartered in Toowong, Australia, the company went public on the NASDAQ in December 2024. Anteris focuses on creating innovative solutions for patients with heart valve disease, particularly through its transcatheter aortic valve replacement technology and proprietary anti-calcification tissue treatment.
Business
Anteris Technologies operates in the structural heart medical device industry, specifically developing products to treat aortic stenosis. Aortic stenosis is a serious heart condition where the aortic valve - which controls blood flow from the heart's main pumping chamber to the rest of the body - becomes narrowed due to calcium buildup or other factors. This narrowing forces the heart to work harder to pump blood, eventually leading to heart failure if untreated. The company's core offerings include three interconnected products that work together to provide a comprehensive solution for aortic valve replacement. The DurAVR transcatheter heart valve system is the company's lead product candidate, designed as a novel transcatheter aortic valve that mimics the performance of a healthy human aortic valve. Unlike traditional surgical valve replacement that requires open-heart surgery, transcatheter procedures allow doctors to insert a new valve through a catheter, typically via an artery in the leg, making it less invasive for patients. Supporting the DurAVR system is the company's proprietary ADAPT anti-calcification tissue technology, which represents a significant innovation in valve durability. This anti-calcification preparation transforms xenograft tissue (typically from animal sources like pigs or cows) into durable bioscaffolds that resist calcium buildup - a major cause of valve failure over time. The ADAPT technology can be used across multiple surgical repair settings beyond just aortic valve replacement. The third component is the ComASUR delivery system, a physician-developed balloon expandable delivery system featuring a reinforced steerable catheter. This system allows for precise navigation through the heart's complex anatomy while minimizing damage to the aorta during valve implantation. Based on the available revenue data showing approximately $2.7 million in annual revenue, the company appears to be in early commercialization stages, likely generating revenue primarily from research partnerships, licensing agreements, or limited commercial sales of its ADAPT tissue technology, as the DurAVR system may still be undergoing clinical trials and regulatory approval processes.
Revenue model
Anteris Technologies generates revenue through multiple channels related to its medical device portfolio. The company's primary revenue model centers on product sales of its medical devices and tissue preparation technologies, particularly the ADAPT anti-calcification tissue which can be licensed or sold to other medical device manufacturers and hospitals for various surgical applications. The company's business model involves significant upfront research and development investments to bring products through clinical trials and regulatory approval processes. Once approved, transcatheter heart valves like the DurAVR system typically generate revenue through direct sales to hospitals and cardiac catheterization laboratories, with pricing often ranging from $20,000 to $40,000 per valve unit, depending on the market and specific product features. The paying customers include hospitals, cardiac surgery centers, interventional cardiologists, and cardiac surgeons who perform these procedures. Additionally, the company may generate revenue through licensing its ADAPT technology to other medical device companies who incorporate the anti-calcification treatment into their own products. Several factors could significantly impact the company's margins and revenue potential. Regulatory approval timelines represent a critical factor, as delays in FDA or international regulatory clearances can postpone revenue generation for years while development costs continue. Clinical trial outcomes directly affect market acceptance and pricing power - superior clinical results enable premium pricing and faster adoption. Competition from established players like Edwards Lifesciences and Medtronic in the transcatheter aortic valve replacement market could pressure pricing and market share. Healthcare reimbursement policies also play a crucial role, as favorable coverage decisions from Medicare and private insurers drive adoption, while restrictive policies can limit market access. Manufacturing scale economies will become increasingly important as the company moves from development to commercial production, with higher volumes enabling better gross margins through reduced per-unit costs.
Competitive moat
Anteris Technologies' competitive moat appears to be moderate but developing, primarily built around its proprietary ADAPT anti-calcification technology and the integrated design of its valve system. The company's strongest defensive position lies in its ADAPT tissue treatment, which addresses one of the most significant long-term challenges in biological heart valves - calcification that leads to valve failure over time. This technology represents genuine intellectual property that could provide sustainable differentiation if clinical data demonstrates superior durability compared to existing solutions. The DurAVR valve's biomimetic design, shaped to replicate natural aortic valve performance, potentially offers clinical advantages that could create physician preference and patient outcome benefits. However, this design-based differentiation may be less defensible over time as competitors can develop similar approaches. The company faces significant competitive threats from well-established players with substantial resources. Edwards Lifesciences and Medtronic dominate the transcatheter aortic valve replacement market with proven products, extensive clinical data, established relationships with physicians, and significant financial resources for continued innovation. These companies have the capability to develop competing anti-calcification technologies or acquire emerging competitors. The medical device industry's high regulatory barriers provide some protection for successful products, but also create substantial risks for companies like Anteris that have not yet achieved full regulatory approval. The company's moat will ultimately depend on demonstrating superior clinical outcomes, particularly regarding valve durability and patient safety, in head-to-head comparisons with established competitors. Without clear clinical superiority, the company may struggle to gain meaningful market share against entrenched competitors with proven track records and established distribution networks.
Risks & safety
The margin of safety appears moderate to concerning given the company's pre-revenue status and high cash burn rate, though recent IPO proceeds provide near-term financial cushion. • Cash position and burn rate: Strong cash position of $48.9 million as of Q1 2025, but burning approximately $21.5 million per quarter in operating cash flow, providing roughly 2-3 years of runway at current burn rates • Debt levels: Very low debt with debt-to-equity ratio of 0.047, indicating minimal solvency risk from leverage • Current liquidity: Excellent current ratio of 3.67 and quick ratio of 3.65, indicating strong short-term liquidity position • Valuation metrics: Company trades at negative earnings multiples due to losses, with price-to-book ratio of 1.24 suggesting reasonable valuation relative to tangible assets • Revenue trajectory: Minimal revenue of approximately $2.7 million annually indicates very early-stage commercialization • Other considerations: High execution risk typical of pre-commercial medical device companies, with success dependent on regulatory approvals, clinical trial outcomes, and market acceptance of unproven products
Recent development
Based on the available financial data, Anteris Technologies has been in a critical development phase focused on advancing its core technologies toward commercialization. The company has maintained relatively stable but minimal revenue of approximately $2.7-3.2 million annually over the past three years, suggesting ongoing research partnerships or limited commercial activities while the primary focus remains on product development. The most significant recent development was the company's initial public offering on NASDAQ in December 2024, which substantially strengthened its financial position. The IPO appears to have raised significant capital, as evidenced by the dramatic improvement in cash position from approximately $10 million in Q3 2024 to over $70 million by Q4 2024. This capital infusion provides the financial runway necessary to advance the DurAVR transcatheter heart valve system through clinical trials and regulatory approval processes. The company's cash burn rate has remained relatively consistent at around $60-75 million annually, indicating sustained investment in research and development activities. The stable revenue base suggests the company may be generating income from its ADAPT anti-calcification technology through licensing agreements or partnerships while developing its primary DurAVR product. The financial trajectory shows the company is in a typical pre-commercial medical device development pattern - high R&D spending, minimal current revenue, but building toward potential significant revenue growth upon regulatory approval and commercial launch. The recent public listing positions Anteris to accelerate its development programs and potentially expand its clinical trial activities for the DurAVR system.
AVR company profile · for informational purposes only — not investment advice.
Track AVR with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free